Epidemiol Psychiatr Sci. 2011 Sep;20(3):219-23. doi: 10.1017/s2045796011000412.
This contribution reviewed the experience of the Cochrane Drugs and Alcohol Group (CDAG) in terms of production of evidence to guide policy and practice. By December 2010, the group had published 55 reviews, with 299 authors involved and 744 primary studies included out of 2114 studies considered for inclusion. 90% of the studies included were randomized controlled trials (RCTs). Considering the 'Implication for practice' section of each review, 31% interventions were classified as to do, 11% as do not do it, 52% to do only in research and for 6% a final judgment was impossible because the reviews included no studies or only one study. These proportions varied according to the type of substance of abuse studied; interventions judged as to do were 42% for alcohol, 32% for opioids, 12% for psychostimulants, 33% for poly drugs, and for prevention. The reviews produced by the CDAG provide evidence on effectiveness of several interventions, and identify areas of uncertainty, where more primary research is needed.
本综述介绍了 Cochrane 药物和酒精组（CDAG）在为政策和实践提供证据方面的经验。截至 2010 年 12 月，该组已发表了 55 篇综述，涉及 299 位作者和 744 项原始研究，其中考虑纳入的研究有 2114 项。90%的研究为随机对照试验（RCT）。考虑到每篇综述的“对实践的启示”部分，31%的干预措施被归类为“应该做”，11%为“不应该做”，52%仅在研究中“应该做”，6%因综述中没有研究或仅有一项研究而无法得出最终结论。这些比例根据所研究的滥用物质的类型而有所不同；被认为“应该做”的干预措施分别为酒精 42%、阿片类药物 32%、苯丙胺类兴奋剂 12%、多种药物 33%和预防。CDAG 发表的综述提供了若干干预措施有效性的证据，并确定了需要进一步开展原始研究的不确定领域。
